XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,240,418 | -11.6% | 65,586 | -0.4% | 0.00% | -33.3% |
| Q2 2023 | $2,534,340 | +21.9% | 65,827 | +13.4% | 0.00% | +50.0% |
| Q1 2023 | $2,078,326 | -3.8% | 58,070 | +6.0% | 0.00% | 0.0% |
| Q4 2022 | $2,160,330 | +37.1% | 54,789 | +25.5% | 0.00% | 0.0% |
| Q3 2022 | $1,576,000 | +56.0% | 43,653 | +31.5% | 0.00% | +100.0% |
| Q2 2022 | $1,010,000 | +9.5% | 33,184 | +10.1% | 0.00% | 0.0% |
| Q1 2022 | $922,000 | +18.7% | 30,150 | +21.1% | 0.00% | – |
| Q4 2021 | $777,000 | +171.7% | 24,904 | +33.2% | 0.00% | – |
| Q3 2021 | $286,000 | -17.3% | 18,698 | +0.4% | 0.00% | – |
| Q2 2021 | $346,000 | -19.9% | 18,617 | -22.7% | 0.00% | – |
| Q1 2021 | $432,000 | +52.7% | 24,091 | +30.4% | 0.00% | – |
| Q4 2020 | $283,000 | +87.4% | 18,478 | +35.0% | 0.00% | – |
| Q3 2020 | $151,000 | -12.2% | 13,685 | 0.0% | 0.00% | – |
| Q2 2020 | $172,000 | +20.3% | 13,685 | -5.7% | 0.00% | – |
| Q2 2019 | $143,000 | – | 14,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,594,932 | $48,518,000 | 10.26% |
| GREAT POINT PARTNERS LLC | 1,104,334 | $33,594,000 | 8.06% |
| ACUTA CAPITAL PARTNERS, LLC | 272,500 | $8,289,000 | 4.62% |
| DAFNA Capital Management LLC | 438,623 | $13,343,000 | 3.64% |
| Parkman Healthcare Partners LLC | 294,559 | $8,960,000 | 3.30% |
| Avoro Capital Advisors LLC | 4,900,000 | $149,058,000 | 2.94% |
| Nan Fung Group Holdings Ltd | 114,380 | $3,479,000 | 2.39% |
| BVF INC/IL | 1,597,966 | $48,610,000 | 2.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 232,630 | $7,077,000 | 2.18% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,391,038 | $133,575,000 | 2.16% |